

INTRODUCING

# Nobivac® DP PLUS



Puppies change lives ●

This changes everything ●

**Nobivac® DP PLUS — An innovative  
breakthrough in puppy protection.**

# Revolutionary puppy protection.

## Unprecedented parvovirus efficacy.

### The importance of early protection



Young puppies are at **high risk** of contracting debilitating or fatal diseases.




**Early immunisation** ensures protection and delivers peace of mind.



Maternally derived antibodies (MDA) provide protection during the first weeks of a puppy's life—but high levels of **MDA can interfere** with vaccination.

### Eliminates the window of susceptibility



INTRODUCING

# Nobivac® DP PLUS



## Introducing the first vaccine capable of breaking through any level of parvovirus MDA from four weeks of age

- Existing parvovirus vaccines are capable of overcoming moderate levels of MDA
- Despite this, there can still be a window of susceptibility, and the puppy will be at risk during this time
- Nobivac® DP PLUS closes the gap

## Nobivac® DP PLUS marks a new era in puppy protection

- No parvovirus MDA interference from four weeks of age
- Delivers a fast onset of immunity (OOI)
  - from 3 days for parvovirus
- Provides cutting-edge protection based on the latest CPV-2c field strain
- Combines trusted distemper protection



INTRODUCING

# Nobivac® DP PLUS

Unsurpassed performance.  
**Remarkable results.**


## The fastest Onset of Immunity (OOI) available

A three-day OOI delivers more immediate parvovirus protection than ever before.

### Nobivac® DP PLUS demonstrated<sup>1</sup>:

- 100% efficacy against clinical signs of parvovirus
- 100% prevention of viral shedding

### Three-day OOI study






## Complete parvovirus MDA breakthrough

No MDA interference eliminates the parvovirus window of susceptibility.

**In a comparative study, only Nobivac® DP PLUS overcame all levels of MDA for effective parvovirus protection<sup>2</sup>**

- Stimulated active immunity in the presence of the highest MDA titres

### Comparative efficacy study



**Nobivac® DP PLUS** does what no other parvovirus vaccine can do ●

INTRODUCING

# Nobivac® DP PLUS

## Tried and trusted. A new level of confidence.




### Proven, reliable distemper protection

- Prevents clinical disease and shedding of virus
- Rapid seven-day OOI
- 99% seroconversion in four- to six-week-old puppies<sup>3</sup>

**Trusted distemper prevention combined with unprecedented parvovirus defence**



Available in convenient 5 x 1-dose presentation



## Nobivac<sup>®</sup> DP PLUS vaccination protocol

Nobivac<sup>®</sup> DP PLUS is intended to be used to provide protection in young pups prior to commencing routine primary vaccination

- Administer a single dose from 4 weeks of age
- Onset of immunity: 3 days for parvovirus  
7 days for distemper virus
- Duration of immunity: up to 8 weeks
- Commence primary vaccination protocol from 8 weeks of age with suitable Nobivac<sup>®</sup> vaccines



INTRODUCING

# Nobivac® DP PLUS



Early protection  
**WITHOUT  
MDA  
INTERFERENCE**  
from four weeks of age



Rapid  
**THREE-DAY  
ONSET OF  
IMMUNITY**



The **FIRST** vaccine  
based on the  
**LATEST CPV-2c  
FIELD STRAIN**



Trusted  
**DISTEMPER  
PROTECTION**

## PARVOVIRUS PROTECTION



The future of puppy protection is here.

Talk to your MSD Animal Health Account Manager today to learn more about this revolutionary new vaccine—Nobivac® DP PLUS or visit [www.msd-animal-health.ie/nobivac-dp-plus-vet](http://www.msd-animal-health.ie/nobivac-dp-plus-vet)

**Nobivac®**   
Protection unites us.

References: 1. Study Report DP PLUS 001 MSD Animal Health. 2. Study Report DP PLUS 003 MSD Animal Health. 3. Study Report DP PLUS 004 MSD Animal Health.

Nobivac® DP PLUS for dogs contains live recombinant canine parvovirus strain 630a ( $10^{5.1} - 10^{6.7}$  TCID<sub>50</sub>) and live attenuated canine distemper virus strain Onderstepoort ( $10^{5.1} - 10^{6.5}$  TCID<sub>50</sub>) and is indicated for active immunisation of dogs from 4 weeks of age onwards to prevent clinical signs and mortality of canine parvovirus infection and canine distemper virus infection and to prevent viral excretion following canine parvovirus infection and following canine distemper virus infection. Moderate to high levels of maternally derived antibodies against canine distemper virus can reduce the efficacy of the product against canine distemper. Maternally derived antibodies against canine parvovirus do not interfere with the efficacy of this product.

Legal category: ROI: **POM** NI: **POM-V**

For further information about side effects, precautions, warnings and contra-indications please consult the product SPC, packaging, leaflets or: MSD Animal Health, Red Oak North, South County Business Park, Leopardstown, Dublin 18, Ireland.

Tel: +353 (0)1 2970220. Email: [vet-support.ie@msd.com](mailto:veter-support.ie@msd.com) Web: [www.msd-animal-health.ie](http://www.msd-animal-health.ie)

**USE MEDICINES RESPONSIBLY**

